Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | CBLB | Q13191 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 12/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866963 | 0.83 | CBLB (0.44) | CBLBPARP1HRH4PARP2 | |
| SCHEMBL7701684 | 0.79 | HRH4 (0.56) | PKN1PKN2HRH4 | |
| SCHEMBL7701682 | 0.77 | PKN1 (0.45) | RIPK1PARP1PKN1PKN2HRH4 | |
| SCHEMBL29866876 | 0.77 | PKN1 (0.45) | RIPK1PARP1PKN1PKN2HRH4 | |
| SCHEMBL7704923 | 0.77 | MAOB (0.50) | RIPK1PARP1PKN1PKN2 | |
| SCHEMBL2321757 | 0.75 | PDK2 (0.41) | PDK2PDK4RIPK1CBLBPARP1 | |
| SCHEMBL20315211 | 0.75 | PKN1 (0.43) | RIPK1PARP1PKN1PKN2HRH4 | |
| SCHEMBL13408238 | 0.75 | CBLB (0.45) | RIPK1CBLBPARP1PKN1PKN2 | |
| SCHEMBL29866837 | 0.75 | CBLB (0.45) | RIPK1CBLBPARP1PKN1PKN2 | |
| SCHEMBL21211892 | 0.73 | HTR1A (0.49) | PDK2PDK4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | PDK2 4528/4885PDK4 4666/4885RIPK1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.